Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Bad
|
|
New words:
ABP, adjacent, affectPegIntron, al, Alaska, alfa, analog, andBridion, andClaritin, andDulera, andDuleraInhalation, andParacox, andProQuad, andRebetol, andSimponi, andSinemet, andTredaptive, andVytorincould, andZetiaand, andZioptan, andZocor, antibacterial, antipsychotic, approvedCosopt, approvedJanumet, approvedJuvisync, approvedSylatron, approvedZioptan, approvedZoely, AQ, art, asDulera, asSaflutan, asSingulairand, asSingularand, asTemodal, asZoely, atherothrombotic, AzaSite, Bauer, Becton, begun, biennial, BioManufacturing, bleeding, block, blockade, Bordetella, Brown, byNuvaRing, CanadianVioxxlitigation, canal, career, Carter, cessation, childbirth, clot, collar, combinesJanuvia, complementary, concede, Congressional, content, cough, David, deadline, debated, deluca, deployed, deprioritized, Dickinson, die, digit, dismissedRose, dissemination, Dodge, drainage, Elkhorn, ERP, exact, exceeded, Femina, femur, finasteride, FlowsConsolidated, forBridion, forDulera, forElonva, forMachinery, forPropecia, forRemicade, forSycrest, Fort, forZoely, fromRemicade, Fujifilm, Gardasil, Garrett, Georgia, guilty, HCI, hematological, hematopoietic, hexavalent, higherCosopt, HyzaarandTemodar, Idaho, inAOCIin, inAOCIuntil, inCarballo, includeGardasil, includingSingulair, incomefrom, inCozaarandHyzaar, inDr, inErnst, infliximab, infusion, inJanuvia, inPedrojetti, inRose, inSecrest, Inspire, interfere, involvingPropecia, Iowa, irrigation, ITC, JJMCP, Joel, kg, knowledge, Lastly, launchCosopt, lengthened, Lenovo, Liechtenstein, lipoprotein, lymphadenectomy, macro, manufactureNuvaRing, marketRemicade, maternal, Maxaltin, medicationJanuvia, medicationZocor, microscopic, Mine, misbranding, misdemeanor, Mississippi, monophasic, MRL, MRSA, Mylanta, Mylicon, narrowed, neuromuscular, NJ, nodal, nomegestrol, ofAOCI, ofClostridium, ofClostridiumdifficile, ofCoppertone, ofCosopt, ofCosoptandTrusopt, ofCozaarandHyzaar, ofEmendincreased, offshore, ofIntegrilin, ofNoxafil, ofPegIntron, ofProQuadwere, ofRemicade, ofRotaTeq, ofVaqta, ofVioxxseeking, ofZoely, ONJ, orOCI, orphan, orVytorin, OTCPepcid, OTCtreatment, pancreatic, peginterferon, Perk, PF, Pisano, plea, plead, Pneumovaxand, polio, posture, preexisting, pregnancy, premium, pretrial, productNuvaRing, productsCosoptandTrusopt, productsZetia, reopen, rescheduled, resection, resubmission, REVEAL, Riverside, rodent, Ronald, Russia, secondFosamax, severalVioxx, sexual, Simponi, subsidized, sudden, summer, surface, suspended, suvorexant, TE, testimony, thatNuvaRing, thatVioxx, theCain, theCarrie, theErnst, theFlemingscase, thePepcid, theSessner, theTemodar, TheWard, theZioptan, toAOCI, toIntegrilinandAvelox, toJanuvia, toPegIntron, toRemicade, Torrent, toSinemet, toSycrest, transplant, tumor, twenty, untreated, vaniprevir, vial, Virginia, VytorinandZetia, wasRaber, weighing, whooping, Wisconsin, withGardasil, withinResearch, withPegIntron, withSessner, woman, ZetiaandNasonex, zone, Zuellig
Removed:
aggressive, agreeable, anesthesia, Argentina, award, BSE, cease, choose, compensatory, confirmed, Crohn, deductible, delivered, Deputy, enrollment, entry, expectation, femoral, fiscal, gained, goal, GP, half, Head, improved, indefinite, independently, inRule, instituted, intervention, invalid, joining, kohan, leadership, mandate, mutual, noncontrolling, oversee, pegylated, pertained, platelet, prevail, procedural, qualifying, raul, refer, repurchase, repurchased, reverse, routine, SCH, science, Scotland, Secretary, statutorily, steering, streamlining, sum, transparent, trust, unlawful, unpaid, unstable, validity, violated, vote, worked
Filing tables
Filing exhibits
- 10-K Annual report
- 10.20 Stock Option Terms for 2012 Quarterly and Annual Non-qualified Option Grants
- 10.21 Restricted Stock Unit Terms for 2012 Quarterly and Annual Grants
- 10.28 Merck & Co., Inc. U.S. Separation Benefits Plan
- 10.29 Important Information on the Separation Program
- 10.30 Important Information on the Separation Program
- 10.31 Important Information on the Separation Program
- 10.32 Important Information on the Separation Program
- 10.33 Important Information on the Separation Program
- 10.34 Important Information on the Separation Program
- 10.35 Important Information on the Separation Program
- 12 Computation of Ratios of Earnings to Fixed Charges
- 21 Subsidiaries of Merck & Co., Inc.
- 24.1 Power of Attorney
- 24.2 Certified Resolution of Board of Directors
- 31.1 Rule 13A-14(A)/15D-14(A) Certification of Chief Executive Officer
- 31.2 Rule 13A-14(A)/15D-14(A) Certification of Chief Financial Officer
- 32.1 Section 1350 Certification of Chief Executive Officer
- 32.2 Section 1350 Certification of Chief Financial Officer
- CORRESP Corresp
Related press release
MRK similar filings
Filing view
External links